Risultati per: Scoperto nuovo biomarker per il cancro al colon-retto

Identifica quelli che rispondono un enzima riparatore del dna

In Reply We appreciate the comments from Ms Lacasse and colleagues regarding our recently published Viewpoint examining the current landscape of state biomarker testing laws.

To the Editor A recent Viewpoint referenced the American Cancer Society Cancer Action Network’s state-by-state campaign to pass legislation ensuring coverage of biomarker testing. We appreciate the attention to our advocacy campaign but disagree with the conclusion that the effect of these laws “may be limited by their lack of reach and implementation challenges.” Given the patchwork nature of the US health care system, it is often necessary to enact consumer protections on both the federal and state levels. We agree that it is important to support clinicians in ordering appropriate tests and interpreting their results, inform patients about biomarker testing, and equip facilities with infrastructure to manage testing, which all fall outside of insurance coverage; however, coverage is a foundational requirement for equitable access. Eighty percent of oncologists reported that insurance coverage for testing was either very or somewhat important in treatment decisions, and current coverage policies are more restrictive than treatment guidelines.

Accuratezza pari o maggiore dei calcolatori in uso

Visita all’Istituto di oncologia molecolare di Fondazione Airc

Adding radiation to NACT increased the R0 resection rate, prolonged the PFS, and potentially improved OS in selected patients with initially unresectable LACC. The trial findings indicate that this approach is safe, feasible, and may confer a survival benefit.

The obesity epidemic is associated with increased colon cancer progression. As lipid droplets (LDs) fuel tumor growth, we aim to determine the significance of diacyltransferases, DGAT1/2, responsible for LDs biogenesis, in obesity-mediated colonic tumorigenesis.

Preservata l’integrità dell’organo, migliora la qualità di vita

Better surveillance tests for hepatocellular carcinoma (HCC) are needed. The GALAD score [Gender, Age, AFP-L3, AFP, and Des-carboxy-prothrombin] has been shown to have excellent sensitivity and specificity for HCC in phase two studies. We performed a phase three biomarker validation study to compare GALAD with AFP in detecting HCC.

Un Progetto della European School of Oncology

Lo rivela una ricerca sul New England Journal of Medicine

Uno studio pubblicato su Nature Communication fa luce su Oser1

Un pericolo per i pazienti fragili soprattutto negli ospedali

Lo ribadisce il più grande studio condotto, incaricato dall’Oms